Subgroup Analysis by Prior Anti-VEGF or Anti-EGFR Target Therapy in FRESCO, a Randomized, Double-Blind, Phase III trial
Rui‐Hua Xu(Sun Yat-sen University), Jin Li(Shanghai East Hospital), Hongbing Wang(China University of Petroleum, East China), Jiejun Wang(Shanghai Changzheng Hospital), Ying Yuan(Zhejiang Cancer Hospital), Shukui Qin(81th Hospital of PLA), Jianfeng Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongming Pan(Sir Run Run Shaw Hospital), Ying Cheng(Jilin Province Tumor Hospital), Haihui Chen(Liuzhou Maternal and Child Health Hospital), Xiaojun Guo(China Banking Regulatory Commission), Yuxian Bai(Harbin Medical University), Ning Wang(Shanghai Ninth People's Hospital), Bin Zhang(Guangzhou University of Chinese Medicine), Jian Li(Beijing Normal University), Wei Li(Jilin University), Donghui Chen(University of Washington), Zhuang Yu(Shanghai East Hospital), Tianshu Liu(Sun Yat-sen University), Shubin Wang(Hebei Medical University), Dong Ma, Haijun Zhong(Zhejiang Cancer Hospital), Jianming Xu(Chinese PLA General Hospital), Zhendong Chen(Anhui Medical University), Weijian Guo, Rubing Han(Shanghai Medical Information Center), Yongqian Shu(Jiangsu Provincial Hospital of Traditional Chinese Medicine), Lei Yang(Nantong Tumor Hospital), Changping Wu(Soochow University), Sanyuan Sun(Xuzhou Central Hospital), Weiguo Su(Tamedia (Switzerland)), Peiguo Cao(Central South University), Nong Xu(First Affiliated Hospital Zhejiang University), Yanhong Deng(Sun Yat-sen University)
Cited by 8
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k